Drugs / GenPHSat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05588401 | Jul 2024 → Jul 2025 | limb-girdle muscular dystrophy | Simone Spuler, MD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenPHsat | “Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.” NCT05588401 ↗ |
| Modality | Cell therapy | “gene edited primary human satellite cell derived muscle stem cells” NCT05588401 ↗ |
| Route | Intramuscular | “Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.” NCT05588401 ↗ |